相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An NFκB Activity Calculator to Delineate Signaling Crosstalk: Type I and II Interferons Enhance NFκB via Distinct Mechanisms
Simon Mitchell et al.
FRONTIERS IN IMMUNOLOGY (2019)
Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
Jixiang Shi et al.
MOLECULAR PHARMACEUTICS (2018)
IRF4 in multiple myeloma-Biology, disease and therapeutic target
Alessandro Agnarelli et al.
LEUKEMIA RESEARCH (2018)
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
Tania Diaz et al.
HAEMATOLOGICA (2017)
Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells
Zhixiang Guo et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy
David Dingli et al.
MAYO CLINIC PROCEEDINGS (2017)
Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease
Hua Bai et al.
ONCOTARGET (2017)
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
Tania Diaz et al.
HAEMATOLOGICA (2017)
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
R. Gopalakrishnan et al.
ONCOGENE (2016)
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
Sameem M. Abedin et al.
ONCOTARGETS AND THERAPY (2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
Andrew R. Conery et al.
ELIFE (2016)
Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities
Eugene L. Piatnitski Chekler et al.
CHEMISTRY & BIOLOGY (2015)
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E. Morelli et al.
LEUKEMIA (2015)
Inhibition of bromodomain and extraterminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence
Aristeidis Chaidos et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
Gene Expression Profiling Identifies IRF4-Associated Molecular Signatures in Hematological Malignancies
Ling Wang et al.
PLOS ONE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination
Ulf Klein et al.
NATURE IMMUNOLOGY (2006)
Regulation of IRF7 through cell type-specific protein stability
A Prakash et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
分享论文
